Share on StockTwits

Ariad Pharmaceuticals (NASDAQ:ARIA) has earned a consensus recommendation of “Hold” from the twenty-three ratings firms that are covering the stock, Stock Ratings Network.com reports. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $6.89.

ARIA has been the subject of a number of recent research reports. Analysts at JMP Securities cut their price target on shares of Ariad Pharmaceuticals from $8.00 to $7.00 in a research note on Thursday. They now have a “market outperform” rating on the stock. Separately, analysts at Chardan Capital reiterated a “buy” rating on shares of Ariad Pharmaceuticals in a research note on Thursday. Finally, analysts at Jefferies Group reiterated a “positive” rating on shares of Ariad Pharmaceuticals in a research note on Monday, June 2nd.

Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 1.29% on Friday, hitting $5.34. The stock had a trading volume of 893,132 shares. Ariad Pharmaceuticals has a 52-week low of $2.15 and a 52-week high of $23.00. The stock’s 50-day moving average is $5.95 and its 200-day moving average is $7.07. The company’s market cap is $995.0 million.

Ariad Pharmaceuticals (NASDAQ:ARIA) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.29) by $0.01. The company had revenue of $12.10 million for the quarter, compared to the consensus estimate of $13.65 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The company’s quarterly revenue was down 13.6% on a year-over-year basis. On average, analysts predict that Ariad Pharmaceuticals will post $-1.14 earnings per share for the current fiscal year.

ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.